Association between haplotype -88G/25G in A2M with Alzheimer's disease

Haiqing Song1, Longfei Jia, Xiumei Zuo

  • 1Department of Neurology, Xuan Wu Hospital of the Capital Medical University, Key Neurodegenerative Laboratory of Ministry of Education of the People's Republic of China, Beijing 100053, PR China.

Insights

Genetic variations in the Alpha 2-Macroglobulin gene (A2M) influence Alzheimer's disease risk. Specific A2M promoter variants, particularly the -88G/25G haplotype, show a protective effect against sporadic Alzheimer's disease.

Area of Science:

  • Genetics
  • Neuroscience
  • Molecular Biology

Background:

  • Alpha 2-Macroglobulin (A2M) gene is a candidate for late-onset Alzheimer's disease (AD).
  • Previous studies on A2M polymorphisms and AD risk have yielded controversial results.
  • The impact of A2M promoter polymorphisms on AD susceptibility remains largely unexplored.

Purpose of the Study:

  • To identify polymorphisms in the A2M promoter region.
  • To evaluate the association between these polymorphisms and sporadic Alzheimer's disease (SAD) risk.

Main Methods:

  • Sequencing identified a single nucleotide polymorphism (-88A/G) in the A2M proximal promoter.
  • This polymorphism, along with a known 25T/G polymorphism, was analyzed in 179 SAD patients and 179 controls.
  • Logistic regression adjusted for age, gender, and APOEε4 allele status.

Main Results:

  • The -88A allele increased SAD risk (OR=1.74), while the 25G allele reduced risk (OR=0.57).
  • Protective effects of -88G and 25G alleles persisted after adjustment for covariates.
  • The -88G/25G haplotype significantly reduced SAD risk (OR=0.56), whereas the -88A/25T haplotype increased risk (OR=1.77).

Conclusions:

  • The A2M promoter haplotype -88G/25G may confer protection against sporadic Alzheimer's disease.
  • The identified protective effects of A2M variants are independent of the APOEε4 allele.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...